<DOC>
	<DOCNO>NCT02341664</DOCNO>
	<brief_summary>The purpose Patient Provider Assessment Lipid Management Registry ( PALM ) gain good understanding physician ' cholesterol medication prescribing practice , patient physician attitude beliefs relate cholesterol management , current utilization cholesterol-lowering therapy give new ACC/AHA guideline recommendation . The PALM Registry hop allow design way improve cholesterol management decrease burden cardiovascular disease ( CVD ) US .</brief_summary>
	<brief_title>Patient Provider Assessment Lipid Management Registry</brief_title>
	<detailed_description>The PALM registry multicenter , observational registry aim evaluate cholesterol management apply current clinical practice . This registry recruit approximately 175 site United States enroll 7,500 patient cardiovascular risk factor warrant consideration lipid-lowering therapy well already statin therapy . Enrolling clinician include primary care provider , internal medicine provider , family medicine provider , cardiologist , endocrinologist . Site selection also target geographic diversity ensure representation region U.S. , include rural urban area , well minority population . This registry unique feature use mobile tablet-based enrollment device . This tablet-based enrollment tool design adapt workflow outpatient practice , allow research procedure ( include screening , informed consent patient survey ) carry patient visit , maximize paper-less data entry . All patient management decision ( include choice cholesterol-lowering therapy ) completely discretion care provider . This registry involve retrospective prospective patient data collection . Baseline data patient physician collect . There patient follow-up . The target sample size ( n=7,500 ) registry determine base statistical consideration , base upon non-probabilistic sampling approach , order obtain sufficient exposure data patient various atherosclerotic cardiovascular disease ( ASCVD ) risk group . During enrollment period , balance across group maintain frequent monitoring enrollment . Adaptive enrollment capping consider ensure adequate exposure across group , physician type , geographic location . Data quality assure web-based application-based data collection tool query data quality report . Data quality control measure include : data entry miss range check , data validation check ; standard record level check run database identify suspect duplicate , blank , miss record ; logic check data surveillance trend data entry query processing . The tool prompt user correct miss , range , potentially incorrect data . There intervention , outside monitor site DSMB registry .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Angina , Unstable</mesh_term>
	<mesh_term>Ischemic Attack , Transient</mesh_term>
	<mesh_term>Carotid Stenosis</mesh_term>
	<criteria>1 . Prior evidence clinical atherosclerotic cardiovascular disease ( ASCVD ) include follow : Hospitalization acute myocardial infarction unstable angina Coronary revascularization chronic coronary artery disease without angina Other arterial ( carotid , abdominal , renal low extremity ) revascularization ( e.g. , surgical bypass , percutaneous intervention , arterial vascular reconstruction , abdominal aortic aneurysm repair , exclude dialysis fistula arteriovenous graft ) . Ischemic stroke transient ischemic attack ( TIA ) Imaging evidence &gt; 70 % diameter stenosis carotid artery clinical documentation severe carotid stenosis Peripheral arterial disease secondary atherosclerosis ( e.g. , aortic aneurysm , ankle brachial index &lt; 0.9 , image evidence &gt; 50 % diameter stenosis peripheral artery , claudication ) 2 . Currently statin therapy 3 . Low density lipoprotein cholesterol ( LDLC ) level ≥ 130 mg/dL within last 2 year ( treat untreated ) 4 . Age ≥ 65 year 5 . Age ≥ 40 year least 1 follow : Diabetes Chronic Kidney Disease ( CKD ) , define eGFR &lt; 60 ml/min document stage III high CKD 10year ASCVD risk ≥ 5 % ( per 2013 ACC/AHA Guideline Assessment Cardiovascular Risk ) 2 follow characteristic : Male sex ; Systolic BP &gt; 140 mmHg medication hypertension ; Current tobacco use 1 . Unable unwilling provide inform consent , include limited cognitive language barrier ( read comprehension ) 2 . Anticipated life expectancy le 6 month 3 . Participation clinical trial involve medical treatment time enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Mobile Tablet Device</keyword>
	<keyword>Outpatient Clinic</keyword>
	<keyword>Tobacco</keyword>
	<keyword>Health</keyword>
	<keyword>Barriers</keyword>
	<keyword>Prevention</keyword>
	<keyword>Prescribing Practices</keyword>
	<keyword>Informed Consent</keyword>
	<keyword>Statin</keyword>
	<keyword>Lipid Panel</keyword>
	<keyword>Low Density Lipoprotein-C</keyword>
	<keyword>Blood Draw</keyword>
	<keyword>ACC/AHA Guidelines</keyword>
	<keyword>Adult Treatment Panel Guidelines ( ATPIII )</keyword>
	<keyword>Atherosclerotic Cardiovascular Disease ( ASCVD )</keyword>
	<keyword>Cholesterol-lowering therapy</keyword>
	<keyword>Cholesterol Management</keyword>
	<keyword>Cardiovascular Risk</keyword>
	<keyword>10-year CVD Risk</keyword>
	<keyword>Labs</keyword>
	<keyword>Coronary revascularization</keyword>
	<keyword>Arterial revascularization</keyword>
	<keyword>Imaging</keyword>
</DOC>